Argenx Bv

Argen-x N.v.

University of Texas System

Argenx Bvba

Peter Ulrichts

Torsten Dreier

Johannes Joseph Wilhelmus De Haard

Karen Silence

Michael John Scott Saunders

Mahan Moshir

Sofie Maria Elvire Gabriels

Harald Wajant

Christophe Blanchetot

Johannes De Haard

E Sally Ward Ober

Nicolas G H Ongenae

Nicolas Leupin

Antonio Guglietta

Hans De Haard

Natalie De Jonge

Anna Hultberg

Thierry Cousin

Tonke Van Bragt

Nicolas Gh Ongenae

Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.

Use of FCRN antagonists for treatment of generalized myasthenia gravis

A method is disclosed for the treatment of human subjects diagnosed with immune thrombocytopenia (ITP). The method comprises administering to a human subject a human neonatal Fc receptor (hFcRn) antagonist, optionally in combination with standard-of-care ITP treatment. In certain embodiments, the hFcRn antagonist is efgartigimod (ARGX-113). Standard-of-care ITP treatment may comprise administration of corticosteroids, immunosuppressants, and/or thrombopoietin receptor (TPO-R) agonists.

Compositions and methods for treating immune thrombocytopenia

Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.

FcRn antagonists and methods of use

The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumour cell growth.

Antibodies to CD70

The present invention relates to antibodies and antigen binding fragments thereof which bind to the human CD70 protein with high affinity and display potent inhibition of tumor cell growth.

FCRN antagonists and methods of use

Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.

Chimeric human-llama antigens and methods of use

Growing community of inventors

Destelbergen, Belgium

Peter Ulrichts